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ABSTRACT
High-grade gliomas (HGG) are the most common brain tumors, with an average 
survival time of 14 months. A glioma-CpG island methylator phenotype (G-CIMP), 
associated with better clinical outcome, has been described in low and high-grade 
gliomas. Mutation of IDH1 is known to drive the G-CIMP status. In some cases, 
however, the hypermethylation phenotype is independent of IDH1 mutation, 
suggesting the involvement of other mechanisms. Here, we demonstrate that DNMT1 
expression is higher in low-grade gliomas compared to glioblastomas and correlates 
with phosphorylated c-Jun. We show that phospho-c-Jun binds to the DNMT1 
promoter and causes DNA hypermethylation. Phospho-c-Jun activation by Anisomycin 
treatment in primary glioblastoma-derived cells attenuates the aggressive features of 
mesenchymal glioblastomas and leads to promoter methylation and downregulation 
of key mesenchymal genes (CD44, MMP9 and CHI3L1). Our findings suggest that 
phospho-c-Jun activates an important regulatory mechanism to control DNMT1 
expression and regulate global DNA methylation in Glioblastoma.
INTRODUCTION
High-grade gliomas are the most common brain 
tumors and are characterized by poor clinical outcome 
with an average survival time of 14 months (glioblastoma, 
WHO grade IV) [1]. In the past few years, glioblastoma 
subgroups characterized by specific gene signatures and 
associated with variable clinical outcome and survival 
have been described [2, 3]. In particular, the mesenchymal 
and the proneural groups appear as the two most robust 
subclasses identified in both studies [2, 3].
Epigenetic gene regulation has emerged as an 
important mechanism controlling gene expression in 
low and high-grade gliomas [4–7]. DNA methylation 
profiling of a large set of gliomas identified a subset 
of samples displaying concerted hypermethylation at 
a large number of loci, indicating the existence of a 
glioma-CpG island methylator phenotype (G-CIMP) 
[5, 7–9]. The G-CIMP tumors belong to the proneural 
subgroup and are associated with longer survival and 
better clinical outcome [5]. Although initially identified 
in a subset of high-grade gliomas, more extensive 
analysis showed that G-CIMP mostly characterizes 
low-grade tumors and confers improved survival [5, 
6]. More recently, Turcan and colleagues identified 
IDH1 mutation as a genetic event responsible for the 
establishment of the G-CIMP phenotype through DNA 
methylation remodeling [6]. Mechanistically, IDH1 
mutation induces accumulation of histone alterations 
such as H3K9me2, H3K27me3 and H3K36me3 which 
in turn promote DNA methylation [6]. Recently, it has 
been shown that IDH1 mutation causes disruption of 
chromosome topology leading to aberrant oncogene 
activation [10].
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The DNA methylatransferase-1 (DNMT1) enzyme 
is the principal maintenance DNA methyltransferase in 
human cancer cells [11], although cooperation of DNMT1 
and DNMT3B is necessary for gene silencing. [12]. 
Additional reports also suggest a partial role of DNMT1 in 
establishing de novo methylation [13–15]. The enhanced 
expression of DNMT1 is responsible for change in the 
methylation patterns of tumor suppressor genes in cancer 
[16–18]. Moreover, increased expression of DNMT1 and 
DNMT3B was recently described in glioblastoma [19].
c-Jun is a basic leucine zipper (bZIP) transcription 
factor that acts as homo- or heterodimer, binding to DNA 
and regulating gene transcription, as part of the activator 
protein-1 (AP-1) complex [20]. Extracellular signals 
can induce post-translational modifications of c-Jun, 
resulting in altered transcriptional activity and target gene 
expression. This activates a number of cellular processes 
such as proliferation, apoptosis, survival, tumorigenesis 
and tissue morphogenesis [20, 21]. The transcriptional 
activity of c-Jun is regulated by environmental stress and 
cytokine-activated MAPK subfamilies which include 
ERK1/2, JNK and p38. JNK and p38 are the two kinases 
predominantly phosphorylating Jun [22, 23], although 
phosphorylation by ERK has been also reported in certain 
cells [24].
Here, we provide evidence for the first time that 
c-Jun N-terminal phosphorylation regulates DNMT1 
expression in lower grade gliomas and proneural 
glioblastoma and promotes a global gene methylation 
profile similar to the G-CIMP phenotype. Our data suggest 
the existence of a c-Jun/DNMT1 pathway that functions as 
a regulator of global methylation in gliomas.
RESULTS
DNMT1 expression is increased in low-grade 
gliomas and is associated with improved survival
To study the role of DNMTs in gliomas, we used 
q-RT PCR to analyze the expression of the three DNA 
methyltransferase enzymes (DNMT1, DNMT3A and 
DNMT3B) in a panel of low and high-grade gliomas 
(n=32) collected at the University Medical Center Freiburg 
(Figure 1A and Supplementary Table 1). The expression 
of DNMT1 was higher in low-grade gliomas compared 
to high-grade tumors (4.57 fold, p-value=0.00059), but 
no difference was observed in DNMT3A and DNMT3B 
expression. The association of DNMT1 expression and 
low-grade gliomas compared to high-grade tumors was 
further validated through analysis of available gene 
expression data from The Cancer Genome Atlas (TCGA) 
(n=1161; fold=1.54; p-value=4.5E-127) (Figure 1B), 
whereas DNMT3A and DNMT3B were more associated 
with high-grade tumors (DNMT3A p-value=2.2E-16, 
DNMT3B p-value=2.1E-15) (Figure 1B). We then asked 
whether DNMT1 expression could also be relevant to 
tumor prognosis. We analyzed DNMT1 expression and 
patient survival data in tumors collected from Freiburg 
and from TCGA and found that DNMT1 was associated 
with improved patient outcome when gliomas from 
different tumor grades were included (p-value=1.1E-4) 
(Figure 1C and 1D). In order to evaluate the role of 
DNMT1 in patient survival within the same category, we 
also analyzed DNMT1 expression and survival separately 
in low and high-grade tumors from TCGA and found 
that DNMT1 was associated with better prognosis in 
low-grade (p-value=0.0021) (Figure 1E) but not in 
high-grade gliomas (p-value=0.9) (Figure 1F), suggesting 
either that high-grade gliomas are more homogeneous 
in terms of DNMT1 expression compared to low-grade 
gliomas or that other mechanisms could be involved.
DNMT1 expression correlates with high DNA 
methylation
Since low-grade gliomas are often characterized by 
the glioma-CpG island methylator phenotype (G-CIMP) 
[6], the high DNMT1 expression level in this tumor group 
could suggest a causal link to DNA methylation. To test 
this hypothesis, we looked at the association between 
DNMT1 expression and DNA methylation in low-grade 
and high-grade glioma samples from TCGA. Interestingly, 
DNMT1 expression was significantly correlated with 
overall CpG methylation level (Spearman-Ranked 
correlation and Fisher’s Extract test for significance niveau 
p<0.05) (Figure 2A) in low-grade gliomas. Analysis 
of different methylated CpGs in low-grade tumors, 
represented as a volcano plot, shows a significantly 
increased (pairwise comparison t-test) methylation (red) 
in the group with high DNMT1 expression and vice versa 
(Figure 2B). A positive correlation with DNA methylation 
was also observed in high-grade gliomas, although to a 
lesser extent (Spearman ranked correlation and Fisher’s 
Extract test for significance niveau p<0.05) (Figure 2C 
and 2D). In a manner similar to what we observed in the 
survival analysis (Figure 1F), this result could be affected 
by the underrepresented highly-methylated high-grade 
tumor samples. Finally, DNMT1 expression analysis in 
TCGA high-grade gliomas classified as mesenchymal 
and proneural showed a higher expression in proneural 
samples (mesenchymal 7.5±0.3; proneural 8.1±0.4, 
p=5.94E-11), consistent with previous findings indicating 
that G-CIMP glioma mostly belong to the proneural 
subtype (Figure 2E).
Phosphorylated c-Jun regulates DNMT1 
expression
A role of c-Jun in the regulation of DNMT1 has 
been previously suggested [25–27]. Moreover, c-Jun has 
been shown to prevent methylation at the CDK6 promoter 
[28, 29]. Based on these earlier studies, we decided to 
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look at the relationship between p-c-Jun, DNMT1 and 
global DNA methylation. Interestingly, we observed a 
significant correlation between DNMT1 RNA levels 
and p-c-Jun in high grade gliomas from TCGA (n=531, 
Pearson correlation=0.3, Baysian predicted correlation 
R=0.37 (95%CI 0.21-0.5), Fischer’s exact test p= 8,9 
x10-5) (Figure 3A–3B). Moreover, in the majority of the 
low-grade gliomas from TCGA samples analyzed, high 
p-c-Jun was also associated with high CpG methylation, 
suggesting a possible mechanistic link between p-c-Jun, 
Figure 1: DNMT1 expression is high in low-grade gliomas and is associated with improved survival and global DNA 
methylation. A. qRT-PCR Analysis of DNMT1, DNMT3A and DNMT3B expression in high-grade and low-grade gliomas from patient 
specimens collected at the University Medical Center Freiburg. B. Microarray analysis of DNMT1, DNMT3A and DNMT3B expression 
in tumor samples of high-grade and low-grade gliomas from the TCGA database. C. Kaplan-Maier and Cox regression analysis of glioma 
samples from Freiburg. D. Kaplan-Maier and Cox regression analysis of all gliomas from the TCGA database. E. Kaplan-Maier and Cox 
regression analysis of low-grade gliomas from the TCGA database. F. Kaplan-Maier and Cox regression analysis of high-grade gliomas 
from the TCGA database.
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DNMT1 and G-CIMP (Spearman’s ranked correlation 
between p-c-Jun protein level and CpG methylation 
and Fisher’s exact test for significance niveau p<0.05) 
(Figure 3C and 3D). A similar result was observed when 
high-grade gliomas were analyzed (Figure 3E and 3F). 
The observed effect of differential methylation was not 
as strong as in low-grade tumors but a high number of 
methylated CpG sites were significantly correlated to p-c-
Jun level (Figure 3E).
We then sought to validate the relationship between 
c-Jun phosphorylation and DNMT1 in patient-derived 
glioblastoma cells. Since no LGG-derived cells with 
characterized DNA methylation levels were available, we 
used glioblastoma-derived mesenchymal and proneural 
cell lines, since these two subtypes are usually G-CIMP- 
and G-CIMP+ respectively. Cell treatment with the 
p-c-Jun activator Anisomycin [30] in the mesenchymal 
cell line BTSC168 resulted in increased JNK and 
c-Jun phosphorylation and DNMT1 protein expression 
(Figure 4A). We noticed that p-c-Jun was higher after 8 
hours and subsequently decreased, while DNMT1 levels 
were more stable, suggesting that other transcription factors 
and/or co-factors could sustain DNMT1 expression in the 
absence of p-c-Jun at later time points. Immunostaining 
also confirmed the increased DNMT1 protein levels (Figure 
4B and 4C). Given the broad spectrum of cell activity by 
Anisomycin, we sought to confirm our findings by using 
a JNK inhibitor. Inhibition of c-Jun phosphorylation by 
the JNK inhibitor SP600125 [31] in a proneural cell line 
(CL3021) expressing high levels of p-c-Jun reduced JNK 
and c-Jun phosphorylation (Figure 4D) and DNMT1 protein 
levels (Figure 4D-4F). qRT-PCR analysis confirmed an 
effect of c-Jun phosphorylation on DNMT1 RNA levels 
upon Anisomycin or SP600125 treatment in BTSC168 and 
CL3021 cells respectively (Figure 4G and 4H). We then 
performed chromatin immunoprecipitation to test binding 
of p-c-Jun at the DNMT1 promoter. Treatment of BTSC168 
with Anisomycin resulted in increased precipitation of the 
DNMT1 promoter, indicating that p-c-Jun binds to the 
DNMT1 promoter and regulates its expression (Figure 4I).
Genome-wide methylation is influenced by c-Jun 
phosphorylation status
We then asked whether c-Jun phosphorylation is 
involved in the establishment of global DNA methylation 
Figure 2: DNMT1 expression is associated with high global DNA methylation in gliomas. A. Correlation analysis of DNMT1 
expression and DNA methylation in low-grade gliomas. B. Volcano plot of low-grade gliomas grouped in high vs low DNMT1 expression. 
C. Correlation analysis of DNMT1 expression and DNA methylation in high-grade gliomas. D. Volcano plot of high-grade gliomas grouped 
in high vs low DNMT1 expression. E. Microarray analysis of DNMT1 expression in tumor samples of high-grade gliomas from the TCGA 
database.
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Figure 3: c-Jun phosphorylation correlates with DNMT1 expression and genome-wide methylation. A-B. Correlation 
analysis of DNMT1 expression and c-Jun phosphorylation levels. C. Stripchart plot showing correlation between p-c-Jun and CpG 
methylation level in low-grade gliomas. D. Volcano plot showing different methylation of high vs. low phosphorylated c-Jun in low-
grade gliomas. E. Stripchart plot showing correlation between p-c-Jun and CpG methylation levels in high-grade gliomas. F. Volcano plot 
showing differential DNA methylation in high-grade gliomas with high vs. low phosphorylated c-Jun.
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in gliomas through regulation of DNMT1 expression. 
To test our hypothesis, cells with active (BTSC168) 
or inhibited (CL3021) JNK pathway were used to 
measure genome-wide DNA methylation changes by 
450k methylation array. Anisomycin-treated BTSC168 
cells revealed a significant increase in genome-wide 
DNA methylation of promoter regions in comparison 
to untreated cells (Figure 5A). Conversely, global 
DNA methylation was reduced in CL3021 cells treated 
with JNK inhibitor SP600125 (Figure 5B). In order 
to understand whether the differentially-methylated 
loci overlap with the previously reported G-CIMP 
Figure 4: c-Jun phosphorylation regulates DNMT1 expression by promoter binding. A. Immunoblot analysis of Jun, p-c-
Jun, JNK, p-JNK, DNMT1 and alpha-tubulin (loading control) expression in a primary mesenchymal cell line (BTSC168) treated with 
Anisomycin as indicated. B. Immunofluorescence analysis of DNMT1 in BTSC168 after Anisomycin treatment. C. Quantification of 
immunostaining shown in B. D. JUN, p-Jun, JNK, p-JNK, DNMT1 and alpha-tubulin expression in a primary proneural cell line (CL3021) 
treated with JNK inhibitor SP600125 as indicated. E. Immunofluorescence analysis of DNMT1 in CL3021 after treatment with SP600125. 
F. Quantification of immunostaining shown in E. G. qRT-PCR of DNMT1 expression after JNK activation in BTSC168. Expression was 
normalized relative to 18s RNA. H. qRT-PCR of DNMT1 expression in CL3021 after JNK inhibition. Expression was normalized relative 
to 18s RNA. I. Plot of ChIP results after JNK activation in BTSC 168 cells. Significance level was defined as *p < 0.05, ***p < 0.005. Error 
bars represent mean ± standard error of the mean (SEM) of at least three independent experiments.
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signature, we performed a gene-set enrichment analysis 
and discovered a significant (p<0.0001) enrichment of 
methylation in the G-CIMP gene-set corresponding to 
c-Jun phosphorylation (Figure 5C). Interestingly, highly 
methylated loci in the G-CIMP signature were also highly 
methylated in BTSC168 upon treatment (Figure 5C). This 
suggests that p-c-Jun causes global methylation changes 
in glioblastoma and low-grade gliomas similar to those of 
G-CIMP by regulating DNMT1 expression.
Phospho-c-Jun epigenetically regulates the 
expression of mesenchymal signature genes
Promoter methylation of three key mesenchymal 
genes (CD44, MMP9 and CHI3L1) already known to 
be regulated by DNA methylation [5, 6, 32] appeared to 
be modified by p-c-Jun activation or inhibition (Figure 
5D and 5E). This suggests that the loss of mesenchymal 
properties could be a consequence of DNA methylation 
changes. Consistent with a role of CD44, MMP9 and 
CHI3L1 in aggressive glioblastoma properties, low 
expression of the three genes was associated with better 
outcome in TCGA samples (Figure 5F). To confirm that 
the epigenetic changes induced by activation or inhibition 
of c-Jun phosphorylation result in mesenchymal gene 
expression changes, protein and RNA levels of CD44, 
MMP9 and CHI3L1 were analyzed. Immunostaining 
of BTSC168 cells treated with Anisomycin showed a 
decrease in protein level for all genes tested (Figure 
6A–6C, top and bottom panels). Concordantly, CD44 
and CHI3L1 mRNA levels were significantly decreased 
after 24h (p=0.00003 and p=0.03 respectively) (Figure 6D 
and 6E) while expression of MMP9 was only transiently 
reduced at 8h (p=0.0003) (Figure 6F). Treatment with the 
JNK inhibitor SP600125 produced an opposite effect as 
immunostaining analysis revealed an increased level of 
CD44, MMP9 and CHI3L1 protein (Figure 6G–6I, top and 
bottom panels). q-RT-PCR showed an increase of CD44 
and CHI3L1 mRNA levels after 48h (p=0.01 and p=0.007 
respectively) (Figure 6J–6K) while MMP9 expression 
was significantly upregulated after 24h (p=0.002) and to a 
lesser extent after 48h (p=0.003) (Figure 6L). These data 
indicate that JNK-pathway-dependent modifications of 
c-Jun phosphorylation status produce epigenetic alterations 
which affect gene expression of key mesenchymal genes.
Previous studies indicate that NF-kB signaling 
could be regulated by c-Jun activation [33–36]. To 
rule out whether DNMT1 could be involved in this 
mechanism, we analyzed NF-kB activity by measuring 
nuclear binding of the canonical p65 NF-kB subunit to 
a kB-responsive sequence. Interestingly, Anisomycin 
treatment led to an increase in p65 binding indicating 
that c-Jun phosphorylation activates NF-kB signaling, 
consistent with previous studies (Supplementary 
Figure 1C). However, DNMT1 silencing did not affect 
NF-kB activity suggesting that other factors downstream 
of c-Jun could be implicated (Supplementary Figure 1C). 
Moreover, DNMT1 reduction was associated with higher 
CHI3L1 protein levels, consistent with a decrease in 
DNMT1-mediated epigenetic regulation (Supplementary 
Figure 1A and 1B). Interestingly, Anisomycin treatment 
did not rescue DNMT1 knockdown effect indicating that 
DNMT1 is required for CHI3L1 transcriptional regulation 
(Supplementary Figure 1A and 1B).
c-Jun N-terminal phosphorylation affects cell 
migration and invasion
Our data indicate that increased levels of c-Jun 
phosphorylation and subsequent induction of DNMT1 
expression are responsible for the G-CIMP/proneural 
phenotype of glioma and adverse to the mesenchymal 
phenotype. Given that mesenchymal glioblastoma are 
characterized by aggressive features such as invasion and 
migration, we analyzed the role of p-c-Jun in such cell 
properties. Migratory properties of JNK-activated and 
inhibited cells was tested via scratch assay. Treatment of 
BTSC168 with Anisomycin resulted in a strong inhibition 
of cell migration compared to controls (Figure 7A). In 
contrast, treatment of CL3021 increased the percentage 
of space covered by the cells (85% vs 70%) after 24h 
(Figure 7B). The result was even more pronounced when 
a second proneural cell line (CL3047) was used (96.5% 
vs 27%) (Figure 7C and Supplementary Figure 2). 
Measurement of cell invasion in BTSC168 treated with 
Anisomycin showed a significant (p=6,8E-15) reduction 
of invasion compared to the control group (Figure 7D). 
Instead, treatment with the JNK inhibitor SP600125 
in proneural CL3021 cells significantly increased cell 
invasion compared to the control (p=1,6E-12) (Figure 7E), 
indicating that inhibition of c-Jun phosphorylation by JNK 
inhibitor increases cell invasion.
DISCUSSION
In this study, we have described a new pathway 
involved in the establishment of global DNA methylation 
profile resembling that of the previously identified 
G-CIMP, a molecular signature associated with improved 
survival in low and high-grade gliomas. We demonstrate 
that highly methylated gliomas contain high levels 
of p-c-Jun compared to sparsely methylated gliomas. 
Interestingly, this pattern correlates with DNMT1 
expression, suggesting a relationship and a regulatory 
mechanism between the two genes. Activation of p-c-Jun 
in a primary mesenchymal cell line leads to increased 
DNMT1 expression and attenuates the aggressive features 
of glioma cells. In addition, we show that increased 
c-Jun phosphorylation leads to changes in global DNA 
methylation patterns towards one that is similar to 
the G-CIMP with concomitant downregulation of key 
mesenchymal genes.
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The G-CIMP was initially reported in glioblastoma 
and associated with the proneural signature, although 
additional analysis integrating lower grade gliomas 
revealed that this phenotype is prevalent in low-
grade tumors and confers improved survival [5, 6, 8]. 
It was demonstrated the IDH1 mutation leads to the 
establishment of the G-CIMP [6, 10]. However, in some 
cases the hypermethylation phenotype also occurs in 
the absence of IDH1 mutations, suggesting that other 
mechanisms could be involved.
Our analysis of p-c-Jun and DNMT1 expression in 
clinical glioma biopsy tissues from TCGA highlighted a 
Figure 5: C-Jun phosphorylation induces genome wide methylation. A-B. Volcano plots showing results of 450k methylation 
array of Anisomycin-treated BTSC168 cells (A) and SP600125-treated CL3021 cells (B). C. Gene Set Enrichment Analysis of differentially-
methylated promotors after Anisomycin treatment (p=0.001). D. Heatmap showing methylation changes at the promoter of candidate genes 
(CD44, MMP9, CHI3L1) in Anisomycin-treated BTSC168 cells (left panel) and SP600125-treated CL3021 cells (right panel). E. Schematic 
representation of CD44, MMP9, CHI3L1 gene loci. The position of CpG regions analyzed in (B) is indicated. F. Kaplan-Maier and Cox 
regression analysis of high-grade gliomas from the TCGA database split into low key-gene expression vs. high key-gene expression (20% 
highest v. lowest).
Oncotarget6948www.impactjournals.com/oncotarget
Figure 6: C-Jun phosphorylation regulates expression of key mesenchymal genes. A-C. Immunofluorescence analysis of 
CD44 (A), CHI3L1 (B) and MMP9 (C) expression upon Anisomycin treatment in BTSC168 cells (top panels). The scale bar represents 
50 μm. Bottom panels: quantification of CD44, CHI3L1 and MMP9 immunostaining. D-F. qRT-PCR analysis of CD44 (D), CHI3L1 
(E) and MMP9 (F) expression in BTSC168 treated with Anisomycin. G-I. Immunofluorescence analysis of CD44 (G), CHI3L1 (H) and 
MMP9 (I) expression upon treatment with JNK inhibitor SP600125 in CL3021 cells. The scale bar represents 50 μm. Bottom panels 
show corresponding quantification. J-L. qRT-PCR analysis of CD44 (J), CHI3L1 (K) and MMP9 (L) expression in CL3021 treated with 
SP600125. Significance level was defined as *p < 0.05, ***p < 0.005. Error bars represent mean ± standard error of the mean (SEM) of at 
least three independent experiments.
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Figure 7: C-Jun phosphorylation reduces cell migration and invasion. A. Microphotographs showing migration of BTSC 168 
cells with or without Anisomycin treatment in a scratch assay experiment. Quantification of each experiment is shown in the corresponding 
right panel. B-C. Scratch assay of CL3021 (B) and CL3047(C) cells after JNK inhibition. Characterization of CL3047 cells is shown in 
Figure 1. Quantification of each experiment is shown in the corresponding right panel. D. Microphotographs showing invading BTSC168 
cells upon JNK activation (left panel) and corresponding quantification (right panel). E. Microphotographs showing invading CL3021 cells 
upon JNK inhibition (left panel) and corresponding quantification (right panel). Significance level was defined as *p < 0.05, ***p < 0.005. 
Error bars represent mean ± standard error of the mean (SEM) of at least three independent experiments.
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good correlation between p-c-Jun and DNMT1, supporting 
previous results in nasopharyngeal carcinoma indicating 
a role of p-c-Jun in DNMT1 regulation [26]. Consistent 
with our data, Tsai and colleagues demonstrated that 
p-c-Jun binds to a DNMT1 promoter inducing DNMT1 
expression and subsequent methylation of the CDH1 
(a.k.a. E-Cadherin) gene. Although only one gene 
promoter was analyzed, it cannot be excluded that p-c-
Jun and consequent DNMT1 regulation in nasopharyngeal 
carcinoma might affect methylation of a larger set 
of genes. A different mechanism, still suggesting a 
connection between c-Jun and DNA methylation, describes 
a new role of c-Jun as a protective factor that prevents 
DNA from being methylated [28, 29]. So, according to 
our model, N-terminal phosphorylation of c-Jun could 
mediate a switch from unmethylated to methylated DNA. 
A recent report indicates that c-Jun/c-Fos heterodimers 
bind to methylated AP1 sites in the genome and activate 
transcription [37]. Although this c-Jun-mediated function 
seems to be in contrast with our reported role of c-Jun 
in mediating methylation, it is possible that c-Jun can 
selectively regulate the expression of a subset of genes 
containing AP1 sites in the promoter.
We show that DNMT1 expression is lower in 
mesenchymal glioblastoma compared to proneural tumors. 
However, since correlation analysis between DNMT1 and 
CpG methylation in high-grade tumors does not distinguish 
between tumor subclasses, it is possible that tumors from 
the classical or neural subtype might also consistently 
show high or low levels of DNMT1. Nevertheless, since 
the highly methylated glioblastoma (G-CIMP) are mostly 
proneural [5], we would mostly expect association between 
DNMT1 expression and DNA methylation in proneural 
samples. In the future, more analysis would be necessary 
to rule out whether an association between DNMT1, CpG 
methylation and the other subclasses exists.
We show that activation of p-c-Jun is associated with 
increased methylation and consequent downregulation of 
three mesenchymal genes which have been previously 
described as key genes involved in the aggressive 
features of mesenchymal glioblastomas [32, 38]. Since 
mesenchymal gliomas are mostly G-CIMP-negative and 
have been identified as belonging to a molecular subclass 
that is mutually exclusive to the often G-CIMP-positive 
proneural tumors, it is possible that methylation and 
consequent downregulation of many mesenchymal genes 
in proneural gliomas is responsible for the improved 
outcome of these tumors. Consistent with this idea, 
we show that the increased methylation by p-c-Jun is 
associated with reduced cell migration and invasion, two 
hallmarks of aggressive gliomas.
Our proposed role of p-c-Jun as a mediator of a 
G-CIMP-like phenotype in glioblastoma differs from 
previous reports showing that levels of c-Jun in gliomas 
correlate with the grade of malignancy and that this 
increase contributes to the malignant properties of the cells 
[39, 40]. Similarly, activation of JNK has been associated 
with increased self-renewal and tumor-initiating capacity 
of glioma stem cells [41–43]. Since our study focuses on 
association of DNMT1 and p-c-Jun with the G-CIMP/
proneural subclass of glioblastoma, it is possible that our 
observed phenotype might specifically characterize this 
glioma subtype and would not be observed in the others. 
Nevertheless, additional studies would be required to clarify 
the role of JNK and c-Jun in low and high-grade gliomas.
In summary, we have demonstrated that 
phosphorylated c-Jun directly binds to and activates 
the DNMT1 gene promoter and represents a novel 
regulatory module of genome-wide methylation status 
in glioblastoma and low-grade gliomas. Since G-CIMP 
tumors have been described as less aggressive and 
characterized by a better outcome, the c-Jun/DNMT1 
pathway could potentially serve as a new target for the 
treatment of glioblastoma.
MATERIALS AND METHODS
Tumor samples and patients
Glioblastoma samples from patients were collected 
at the Department of Neurosurgery, University Medical 
Center Freiburg, Germany. Retrieval and scientific 
analysis of patient-derived tissue was approved by the 
local ethics committee under protocol 100020/09. Written 
informed consent was obtained from all patients. Further 
analysis was performed on 537 glioblastoma samples 
collected as part of The Cancer Genome Atlas (TCGA) 
Pilot Project (http://cancergenome.nih.gov/).
Cell lines and cell culture
The primary brain tumor stem cells (BTSCs) were 
prepared from tumor specimens collected at the University 
of Freiburg (BTSC168) or University of Uppsala (CL3021 
and CL3047) and grown as neurospheres in Neurobasal 
medium (Invitrogen) containing B27 supplement 
(Invitrogen), FGF (20 ng/ml, R&D Systems), EGF 
(20 ng/ml, R&D Systems), LIF (10 ng/ml, Genaxxon 
biosciences), Heparin (2 µg/ml, Sigma) and glutamax 
(Invitrogen). For CL3021 and CL3047 culture, N2 
supplement (Invitrogen) was added. To activate the JNK-
pathway, 1μl/ml Anisomycin (Sigma Aldrich) was added 
to cell culture medium according to the manufacturer’s 
instructions. For inactivation of the JNK-pathway, cells 
were treated with 50μmol/ml SP600125 (Invivogene) 
according to the manufacturer’s instructions.
Classification of brain tumor cells
The classification of BTSCs previously profiled by 
gene expression array (Illumina HumanHT-12v3) was 
performed using 510 genes out of the 840 classifier genes 
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used by Verhaak et al. to classify 260 glioblastoma samples 
(Verhaak et al., 2010), and 529 glioblastoma tissue samples 
from TCGA with assigned subtypes as reference (Cancer 
Genome Atlas Research Network, 2008). The 510 genes 
were selected for their concordance with the extended set 
of 529 TCGA samples and representation on the Illumina 
HumanHT-12v3 expression BeadChip arrays. The 
expression levels for these genes on the Illumina arrays 
and in the TCGA data set were converted into z-scores 
and the combined matrix was used to classify each BTSC 
sample based on a k-nearest neighbors (k=10) and voting 
procedure, in which a subtype was assigned based on 
the majority subtype among the 10 TCGA samples with 
highest correlation coefficients for these genes with 
respect to the BTSC sample. All data manipulations were 
performed in R (R Core Team, 2012) and MATLAB (The 
MathWorks, Inc., Natick, MA, United States).
Immunoblotting and immunostaining
The following antibodies were used in 
immunoblotting analyses: phospho-c-Jun (Ser73) 
(Cell Signaling dilution: 1:500), c-Jun (Cell Signaling 
dilution: 1:1000), DNMT1 (Abcam dilution: 1:1000), 
JNK (Santa Cruz, dilution: 1:5000), phospho-JNK 
(Santa Cruz, dilution: 1:5000), and α-tubulin (mouse 
monoclonal, Abcam). Primary antibodies were used at 
the concentration indicated by the manufacturers. Anti-
Mouse and anti-Rabbit HRP-conjugated (Santa Cruz, 
dilution: 1:5000) were used as secondary antibodies. 
Immunostaining was performed using antibodies against 
DNMT1 (Abcam dilution: 1:200), CD44 (Abcam dilution: 
1:200), CHI3L1 (Quidel dilution: 1:150) and MMP9 (Cell 
signaling dilution: 1:200). Primary antibodies were used 
at the concentration indicated by the manufacturers. Anti-
Mouse, anti-Rabbit and anti-Goat Alexa594- or Alexa647-
conjugated (Life Technologies) were used as secondary 
antibodies. Alexa594-conjugated antibodies were used at 
1:200 dilution and Alexa647-conjugated antibodies were 
used at 1:100 dilution. Pictures were acquired using a 
fluorescent microscope (FL10i, Olympus).
Quantitative real-time PCR
Total RNA was prepared using the RNeasy kit 
or the All Prep DNA/RNA Protein Mini Kit (Qiagen) 
and used for first strand cDNA synthesis using random 
primers and SuperscriptIII Reverse Transcriptase 
(Invitrogen). Quantitative real-time PCR (qRT-PCR) was 
performed using a SYBR Green PCR Master Kit (Applied 
Biosystems). The following primers were used: DNMT1-
for: AGGCGGCTCAAAGATTTGGAA; DNMT1-rev: 
GCAGAAATTCGTGCAAGAGATTC; DNMT3A-for: 
GTCATGTGGTTCGGAGACGG; DNMT3A-rev: AGT 
GTCACTCTCATCGCTGTC; DNMT3B-for: CCCAGCT 
CTTACCTTACCATCG; DNMT3B-rev: GGTCCCCTAT 
TCCAAACTCCT; CD44-for: GCAACTGAGACAGCA 
ACCAAG; CD44-rev: GCCATTTGTGTTGTTGTGTG 
AA; CHI3L1-for: CCACCCTAATCAAGGAAATGA; CH 
I3L1-rev: TGAAATCCAGGTGTTGGGATA; MMP9- 
for: TGTACCGCTATGGTTACACTCG; MMP9-rev: 
GGCAGGGACAGTTGCTTCT; 18srRNA-for: TTTGCG 
AGTACTCAACACCA; 18srRNA-rev: CCACACCCCT 
TAATGGCA
Migration and invasion assays
For the wound-healing assay, cells were plated in 
60 mm dishes and grown at 95% confluence. A scratch 
of approximately 1 mm was made with a p1000 pipette 
tip and fresh medium containing 1μl/ml Anisomycin or 
water was added to the cells. Pictures were taken after 
0h, 2h and 12h. For the JNK inactivation experiment, 
SP600125 or DMSO was added and pictures were 
taken after 0h, 6h and 24h. Images were taken using a 
wide-field microscope (Axiovert, Zeiss). The Matrigel 
invasion assay was performed using BioCoat Matrigel 
Invasion Chambers (BD Bioscience) according to the 
manufacturer’s instructions. 8000 cells/well were seeded 
in the upper compartment and incubated with Anisomycin 
or SP600125. PDGF-BB (20ng/ml, R&D) was used as 
a chemoattractant. After the incubation, cells were fixed 
with formaldehyde and stained with crystal violet.
Methylation array and gene set enrichment 
analysis (GSEA)
The methylation array was performed using the 
Illumina Infinium HumanMethylation450 chip according 
to the manufacturer’s instructions (DKFZ, Heidelberg). 
Data analysis was performed by R software and RnBeads 
software package. Quality control was done by major 
quality control algorithms including sample-independent 
controls. Normalization of the raw data was done by 
SWAN and BMIQ procedures. Differential methylation 
on the promoter level was computed based on a variety of 
metrics. Differential methylation analysis was performed 
by limma package. Gene-set Enrichment Analysis 
(GSEA) was performed by GSEA tool (http://software.
broadinstitute.org/gsea/index.jsp). G-CIMP gene set was 
defined as a promoter set including 100 most differently 
methylated gene promoters as described in Noushmehr et 
al. (2010).
Chromatin immunoprecipation
Chromatin immunoprecipitation (ChIP) was 
performed as previously described [44]. 4x107 BTSC168 
cells treated with Anisomycin (8h) or controls were fixed 
with 1% formaldehyde for 15 minutes and stopped with 
0.125M glycine for 5 minutes and washed twice with PBS. 
Cells were harvested using SDS buffer with 1X Protease 
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inhibitor and PMSF (Phenyl Methyl Sulfonyl Fluoride) 
and centrifuged at 1200rpm/6min at 4°C. The pellet 
was suspended in 3 ml of ice-cold immunoprecipitation 
buffer. Samples were sonicated and the sonicated lysates 
were precleared with Protein A/G beads (Santa Cruz) 
and incubated at 4°C overnight with 3 μg of polyclonal 
antibody specific for phospho c-jun (rabbit polyclonal, 
Cell Signalling) or normal rabbit immunoglobulins 
(Santa Cruz). DNA was eluted in 200 μl of water and 
the immunoprecipitated DNA was analyzed by absolute 
qRT-PCR. The amplification product was expressed as 
percentage of the input for each condition. The following 
primers were used to amplify sequences surroundings 
predicted c-Jun binding sites at the DNMT1 locus: 
DNMT1_forward: GAAAGTTTAAGGCCGGGCAC, 
DNMT1_reverse: GATCACTGC-AGCCTCTACCT.
Vectors and lentiviral infection
Lentiviral infections were performed as previously 
described [45]. Knockdown of DNMT1 was obtained 
with a shRNA lentiviral vector (pLKO, Sigma Clone ID 
TRCN0000021891). Upon infection cells were selected 
with Puromycin (0.5 μl/ml) for 24 hours.
Nuclear and cytoplasmic extracts and NF-kB 
DNA binding assay
Cytoplasmic and nuclear extracts were prepared 
using a Nuclear Extract Kit (Active Motif) and processed 
using the TransAM assay p65 kit according to the 
manufacturer´s instructions.
Statistical analysis
Expression analysis of the TCGA data was 
performed by R software. TCGA samples were extracted 
from the TCGA database and lowess normalized. 
Expression fold change was calculated by the log2 ratios 
of intensities. Statistical significance was defined as p 
< 0.05 for all statistical tests. For methylation analysis 
of TCGA samples, level 3 methylation data (Illumina 
Infinium HumanMethylation450 chip) were extracted 
from the TCGA database and normalized. Analyses 
were done as described above. For survival analysis, 
the Kaplan-Meier method was used to provide median 
point estimates and time-specific rates. The ANOVA 
model was used in univariate and multivariate settings to 
identify significant factors associated with the treatment. 
Log-rank, Wilcoxon and Tarone-Ware tests were used to 
analyze survival parameters such as OS and PFS. The 
Hazard-Ratio (HR) was calculated by Cox-Regressions 
tests. Statistical significance was defined as p < 0.05 for all 
statistical tests. A regression model was used to correlate 
c-Jun phosphorylation and DNMT1 gene expression by 
maximum likelihood estimation (MLE). Additionally, 
a Baysian regression model was performed based on 
the Markov Chain Monte Carlo (MCMC) algorithm to 
calculate a probability distribution and predict unknown 
parameter. Both models showed a robust correlation. All 
statistical analyses were performed using R-software and 
R-software tools or IBM SPSS Statistics version 22. Plots 
were done by R-software package ggplot2.
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